INDICATIONS FOR TESTING
Predict response to PD-L1 inhibitors in patients with varied malignancies

PD-L1 inhibitor therapy

Cemiplimab-rwlc (LIBTAYO)
ORDER
PD-L1 22C3 IHC with Tumor Proportion Score (TPS) Interpretation, pembrolizumab (KEYTRUDA) and cemiplimab-rwlc (LIBTAYO)
COMPANION diagnostic testing (testing is REQUIRED for use of KEYTRUDA and LIBTAYO for these tumor types)

Pembrolizumab (KEYTRUDA)
ORDER
PD-L1 22C3 IHC with Combined Positive Score (CPS) Interpretation, pembrolizumab (KEYTRUDA)*
COMPANION diagnostic testing (testing is REQUIRED for use of KEYTRUDA for these tumor types)

Nivolumab (OPDIVO)
ORDER
PD-L1 28-8 pharmDx by Immunohistochemistry with Interpretation, nivolumab (OPDIVO)®
COMPETENTARY diagnostic testing (testing is NOT REQUIRED for use of OPDIVO for these tumor types)

Nivolumab (OPDIVO) plus ipilimumab (YERVOY)
ORDER
PD-L1 28-8 pharmDx by Immunohistochemistry with Interpretation, nivolumab (OPDIVO)
COMPANION diagnostic testing (testing is REQUIRED for use of OPDIVO and YERVOY for this tumor type)

Abbreviations
ESCC Esophageal squamous cell carcinoma
GEJ Gastroesophageal junction
HNSCC Head and neck squamous cell carcinoma
NSCLC Non-small cell lung cancer
MMR Mismatch repair
MSI Microsatellite instability
TNBC Triple-negative breast cancer

*Nivolumab (OPDIVO) plus ipilimumab (YERVOY) is only approved for patients with melanoma

**PD-L1 SP142 for treatment with atezolizumab (TECENTRIQ) and PD-L1 SP263 for treatment with durvalumab (IMFINZI) tests are also available for ordering at some laboratories.

© 2017 ARUP Laboratories. All Rights Reserved. www.arupconsult.com
Content reviewed: September 2021
Last update: September 2021